Similarly, MSI and dMMR have been suggested as predictive biomarkers of response to anti-PD-1/L1 antibodies, irrespective of tumor type [83]; however, these phenotypes are also not sufficient to fully predict drug response since they are frequently observed in many cancers and therefore lack specificity [49, 84]. Here, PDCD1 is linked to cancer.